Scientists reprogram Patients' own immune cells to fight advanced gynecologic cancers

NCT ID NCT05468307

Summary

This early-phase study tested a new treatment called GC203 TIL for advanced gynecologic cancers. Doctors took immune cells from patients' tumors, genetically modified them to be more powerful, grew large quantities, and infused them back into 26 patients who had run out of standard treatment options. The main goals were to check if this personalized cell therapy was safe and if it could shrink tumors or control cancer growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT SIDE EFFECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, 200000, China

Conditions

Explore the condition pages connected to this study.